Register for our free email digests:
Latest From Actelion Pharmaceuticals Ltd.
US sales were down 14%, but much of the hit was due to a 2016 price adjustment that was felt across the pharma portfolio, and execs insisted the impact of biosimilars is more moderate than expected.
In Vivo's editors pick June's most significant deals, including Idorsia's IPO and Medtronic's outcomes-based contract with Aetna. (Free article.)
Arena reported statistically and "clinically" significant results from its Phase II study for ralinepag in pulmonary arterial hypertension (PAH), driving its share price up by more than 40%, but details expected later this year or in 2018 are needed to shed more light on the data.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- HealthWatch Inc.
- Senior Management
Daniel J Kelly, CEO
Robert Hirsekorn, CFO
Allen Goldstone, SVP
- Contact Info
Phone: (760) 598-4333
3525 Piedmont Rd., Ste. 300
Atlanta, GA 30350
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.